Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2770 | PF-07104091 monotherapy Wiki | 0.71 |
| drug2768 | PF-07104091 + palbociclib Wiki | 0.71 |
| drug2769 | PF-07104091 + palbociclib + letrozole Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D055752 | Small Cell Lung Carcinoma NIH | 0.50 |
| D010051 | Ovarian Neoplasms NIH | 0.41 |
| D002289 | Carcinoma, Non-Small-Cell Lung NIH | 0.32 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0030357 | Small cell lung carcinoma HPO | 0.50 |
| HP:0100615 | Ovarian neoplasm HPO | 0.41 |
| HP:0030358 | Non-small cell lung carcinoma HPO | 0.32 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0100526 | Neoplasm of the lung HPO | 0.20 |
Navigate: Correlations HPO
There are 2 clinical trials
To evaluate the safety, toxicity and immunological effects of infusion of allogeneic bone marrow-derived human mesenchymal stem (stromal) cells (MSCs) and whether this therapy has an influence on the resolution processes in ARDS patients infected with Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Description: improvement of lung injury score (LIS), 0-16 points, severity increasing with higher points
Measure: lung injury score Time: day 10Description: D-dimers blood levels
Measure: D-dimers Time: day 0, 1, 2, 3, 10 and 15Description: distribution of phenotypes of immune cells
Measure: phenotype Time: day 0, 1, 2, 3, 10 and 15Description: Levels of specialized pro-resolving lipid mediators within alveolar macrophages and bronchoalveolar lavage
Measure: pro-resolving lipid mediators Time: day 0, 1, 2, 3, 10 and 15Description: Cytokine concentration within bronchoalveolar lavage and Serum prior and after MSC infusions
Measure: cytokines Time: day 0, 1, 2, 3, 10 and 15Description: Chemokine concentration within bronchoalveolar lavage and Serum prior and after MSC infusions
Measure: chemokines Time: day 0, 1, 2, 3, 10 and 15Description: Survival at 10 days and 28 days
Measure: Survival Time: day 10 and 28Description: Time to removal of endotracheal tube
Measure: extubation Time: day 28Description: lymphocyte subpopulations in peripheral blood by flow cytometry prior and after MSC infusion (day 0,3,5,10)
Measure: lymphocyte subpopulations Time: day 0, 3, 5 and 10Description: evaluate SARS-CoV-2-specific antibody titers in the serum of patients prior and post MSC infusion.
Measure: SARS-CoV-2-specific antibody titers Time: day 0, 5 and 10Description: evaluate levels of complement molecules (C5-C9) in the serum of patients prior and post MSC infusion
Measure: complement molecules (C5-C9) Time: day 0, 5 and 10The propose of this study is implement adjuvant therapy with adipose tissue derived-mesenchymal stem cells (MSCs) for critical COVID-19 patients admitted to the intensive care unit of the Regional Hospital Lic. Adolfo López Mateos of the Institute for Social Security and Services for State Workers to reduce cytokine storm and contribute to the favorable resolution of respiratory insufficiency and multiple organic failure.
Description: Pulmonary lesion area will be taken by a chest x-ray or computed axial tomography
Measure: Change form baseline in Arterial oxygen saturation Time: up to 25 daysDescription: Aretrial oxygen saturation will be taken by an oximeter
Measure: Change form baseline in Arterial oxygen saturation Time: up to 25 daysDescription: Number of days of patient discharge
Measure: Days to clinical improvement Time: up to 25 daysDescription: Blood samples will be taken on days 1, 3, 7, 15, 20, 25
Measure: Change Form Baseline in C reactive protein at 25 days Time: up to 25 daysDescription: Blood samples will be taken on days 1, 3, 7, 15, 20, 25
Measure: Change Form Baseline Immune cells: CD3+, CD4+, CD8+, CD16+, CD19+, and CD56+ lymphocytes Time: up to 25 daysDescription: Blood samples will be taken on days 1, 3, 7, 15, 20, 25
Measure: Change Form Baseline in pro-inflammatory cytokines: IL-1β, IL- 2, TNF-α, ITN-γ, IL-4, IL-6, IL-10 Time: up to 25 daysDescription: Blood samples will be taken on days 1, 3, 7, 15, 20, 25
Measure: Change Form Baseline in Immunoglobulins; IgA, IgG, IgM, and IgE. Time: up to 25 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports